🔎 Trials Near Me

Почетна › Рак дојке › Nevada

Kliničke studije za Рак дојке u državi Nevada

22 studija za Рак дојке traži učesnike na lokacijama u državi Nevada.

Gradovi u državi Nevada

Zvanični tekst studije (na engleskom)

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

  • Renown Regional Medical Centre, Reno
  • Cancer Care Specialists, Reno
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT05696626

A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)

  • Renown Health Conrad Breast Center at South Meadows, Reno
Тражи се учесникФаза 3
Узраст 18 и старији · Жене · Ажурирано 12. 11. 2026. · NCT07541079

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

  • Optum Care Cancer Center ( Site 0050), Las Vegas
  • Renown Regional Medical Center ( Site 0041), Reno
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06966700

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

  • Renown Regional Medical Center, Reno
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT03424005

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

  • Comprehensive Cancer Centers of Nevada, Las Vegas
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07029399

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  • Renown Health Medical Oncology, Reno
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06982521

E-Mindfulness Approaches for Living After Breast Cancer

  • Renown Regional Medical Center, Reno
Тражи се учесникФаза 3
Узраст од 18 до 50 · Оба пола · Ажурирано 4. 11. 2026. · NCT06748222

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Carson Tahoe Regional Medical Center, Carson City
  • Comprehensive Cancer Centers of Nevada - Henderson, Henderson
  • Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson
  • и још 24
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст од 40 до 75 · Оба пола · Ажурирано 4. 11. 2026. · NCT05334069

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  • OptumCare Cancer Care at Seven Hills, Henderson
  • OptumCare Cancer Care at Charleston, Las Vegas
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06418204

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  • Carson Tahoe Regional Medical Center, Carson City
  • Comprehensive Cancer Centers of Nevada - Henderson, Henderson
  • Comprehensive Cancer Centers of Nevada-Horizon Ridge, Henderson
  • и још 24
Тражи се учесникФаза 3
Узраст од 18 до 60 · Жене · Ажурирано 4. 11. 2026. · NCT05879926

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

  • Cancer Care Specialists ( Site 9503), Reno
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07060807

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

  • Research Site, Reno
Тражи се учесникФаза 3
Узраст од 18 до 130 · Оба пола · Ажурирано 19. 10. 2026. · NCT07647328

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  • Comprehensive Cancer Centers of Nevada, Henderson
  • Comprehensive Cancer Centers of Nevada, Henderson
  • Comprehensive Cancer Centers of Nevada, Las Vegas
  • и још 9
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 19. 10. 2026. · NCT07062965

T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd

  • Comprehensive Cancer Centers of Nevada, Las Vegas
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 16. 10. 2026. · NCT07683754

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

  • Cancer Care Specialists, Reno
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 1. 10. 2026. · NCT06369285

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

  • Cancer Care Specialist of Reno, Reno
Тражи се учесникОпсервациона студија
Узраст од 18 до 99 · Оба пола · Ажурирано 3. 9. 2026. · NCT07211178

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

  • Comprehensive Cancer Centers of Nevada, Las Vegas
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 21. 8. 2026. · NCT06764940

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

  • Comprehensive Cancer Centers of Nevada, Henderson
Тражи се учесникФаза 3
Узраст од 18 до 100 · Оба пола · Ажурирано 6. 8. 2026. · NCT05232916

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

  • Comprehensive Cancer Centers of Nevada, Las Vegas
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 29. 6. 2026. · NCT05377996

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

  • OptumCare Cancer Care at Seven Hills, Henderson
  • OptumCare Cancer Care at Charleston, Las Vegas
  • Radiation Oncology Centers of Nevada Central, Las Vegas
  • и још 8
Тражи се учесникФаза 3
Узраст од 50 до 70 · Оба пола · Ажурирано 23. 4. 2026. · NCT04852887

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

  • Comprehensive Cancer Centers of Nevada, Las Vegas
Тражи се учесникФаза 1
Узраст 18 и старији · Жене · Ажурирано 22. 4. 2026. · NCT05683418

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

  • Renown Regional Medical Center, Reno
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 22. 9. 2025. · NCT05216432

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.